Skip to main content
340BHealth Plan EnrollmentLGBTQ+

The Rising Concern Over Antibiotic Resistance from DoxyPEP Use

July 16, 2025

Balancing STI Prevention and Antibiotic Stewardship

DoxyPEP—doxycycline taken within 72 hours after sex—has shown promising results in reducing syphilis, chlamydia, and even gonorrhea. However, increasing use has triggered rising levels of antibiotic resistance, particularly in tetracycline-resistant gonorrhea, sparking caution among health experts.

While doxyPEP is effective—studies show it lowers chlamydia and syphilis by up to 88–90%, and gonorrhea by roughly 55%—recent data reveal alarming resistance trends. One study found tetracycline-resistant gonorrhea rose from 27% to 70% between 2017 and 2024 in Seattle clinics. Resistance also appeared in Staphylococcus aureus and group A Streptococcus, underscoring a broader public health concern.

Why This Matters

  • STI Effectiveness vs. Resistance Risk: DoxyPEP delivers high STI prevention rates, but resistance, particularly in gonorrhea, threatens its long-term efficacy.

  • Bystander Bacteria Affected: Resistance isn’t limited to STIs—commensal bacteria are showing increased antibiotic resistance, meaning doxyPEP may disrupt normal flora and antibiotic effectiveness.

  • Need for Surveillance: Experts emphasize establishing antimicrobial-resistance monitoring systems and using doxyPEP under targeted, controlled conditions.

Key Principles for Responsible Use

  1. Targeted Prescribing: Reserve doxyPEP for individuals at high STI risk—such as those recently treated for syphilis or chlamydia.

  2. Robust AMR Monitoring: Track microbial resistance in both STI pathogens and bystander bacterial populations.

  3. Patient Education: Inform users that doxyPEP is not a replacement for condoms and discuss possible side effects and resistance implications.

  4. Adaptive Guidelines: Update protocols rapidly based on emerging resistance, particularly for gonorrhea and co-infections.

How American Exchange Can Support Implementation

Effective rollout of doxyPEP demands systems that support monitoring, outreach, and compliance. American Exchange’s platform provides:

  • Targeted patient stratification: Identify individuals most likely to benefit while limiting overexposure.

  • Automated AMR alerts: Flag trends in resistance and adapt protocols accordingly.

  • Education and follow-up workflows: Ensure patients understand doxyPEP’s use and complete testing.

  • Reporting dashboards: For clinics to monitor resistance and inform policy.

Schedule a demo to explore how we can help your organization implement doxyPEP safely:
👉 Schedule a demo

Source:
University of Washington–CIDRAP. “Study hints doxyPEP use coincides with rise in tetracycline-resistant gonorrhea in US.” July 12, 2025. Available at: https://www.cidrap.umn.edu/antimicrobial-stewardship/study-hints-doxypep-use-coincides-rise-tetracycline-resistant-gonorrhea